Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio Unloads Part of Its Capital Equipment Biz for $1M, Plus Earn-out

NEW YORK (GenomeWeb News) - Harvard Bioscience said yesterday that it has sold its Genomics Solutions division and Maia Scientific business to Digilab for $1 million in cash and a 20 percent earn-out of the revenue the businesses generate over a three-year, post-transaction period.
Both businesses were part of the company’s Capital Equipment Business Segment, which Harvard Bio has been trying to sell for more than two years.
Harvard Bio will hold the rights to certain deferred tax assets, which the company said are currently offset by valuation allowances.
The firm said it still is looking to sell its COPAS flow cytometry products, which are held under its Union Biometrica US and German subsidiaries and were not a part of the Digilab deal.
Harvard Bio President David Green said the divestiture of the capital equipment division will allow the firm to “focus our resources on our apparatus and instrumentation business and to continue our pursuit of tuck-under acquisitions.”

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.